News
LTRN
3.130
+1.62%
0.050
Weekly Report: what happened at LTRN last week (1118-1122)?
Weekly Report · 1d ago
Lantern Pharma doses first patient in LP-300 trial expansion cohort
TipRanks · 11/19 13:21
LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN JAPAN FOR THE EXPANSION COHORT IN THE PHASE 2 HARMONIC™ CLINICAL TRIAL OF LP-300 IN NEVER-SMOKER NSCLC PATIENTS
Reuters · 11/19 13:00
Weekly Report: what happened at LTRN last week (1111-1115)?
Weekly Report · 11/18 11:29
Weekly Report: what happened at LTRN last week (1104-1108)?
Weekly Report · 11/11 11:45
Lantern Pharma Discusses Q3 Financial Results Webinar
TipRanks · 11/08 11:28
Lantern Pharma Advances AI-Driven Cancer Therapies
TipRanks · 11/08 04:48
Lantern Pharma Q3 2024 GAAP EPS $(0.42) Beats $(0.56) Estimate
Benzinga · 11/07 21:40
Lantern Pharma reports Q3 EPS (42c), one estimate (56c)
TipRanks · 11/07 21:26
STARLIGHT THERAPEUTICS ANNOUNCES INAUGURAL MEMBERS OF SCIENTIFIC ADVISORY BOARD
Reuters · 11/05 13:00
Weekly Report: what happened at LTRN last week (1028-1101)?
Weekly Report · 11/04 11:41
Press Release: Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Dow Jones · 10/31 12:03
Weekly Report: what happened at LTRN last week (1021-1025)?
Weekly Report · 10/28 11:32
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Barchart · 10/23 07:45
Weekly Report: what happened at LTRN last week (1014-1018)?
Weekly Report · 10/21 11:28
Lantern Pharma granted fast track designation for LP-184
TipRanks · 10/15 13:16
LANTERN PHARMA INC - PHASE 1B/2A TRIAL FOR RECURRENT GBM TO START LATE 2024
Reuters · 10/15 13:07
Weekly Report: what happened at LTRN last week (1007-1011)?
Weekly Report · 10/14 12:00
Weekly Report: what happened at LTRN last week (0930-1004)?
Weekly Report · 10/07 11:48
More
Webull provides a variety of real-time LTRN stock news. You can receive the latest news about Lantern Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform with multiple clinical-stage drug programs. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 60 billion oncology-focused data points and a library of over 200 advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.